Novo Nordisk A/S

(New York Stock Exchange)
Back to all articles
Slightly Bearish -15

Novo Nordisk's Oral Wegovy Data Land as CFRA Turns Bearish on the Stock

Analyst downgrade Clinical trial results Company update AI-generated analysis

πŸ“Š Novo Nordisk published real-world data showing a 4.1% average weight loss in patients switching from injectable to oral Wegovy over three months.

🩺 A retrospective study of 636,525 type 2 diabetes patients indicated that escalating semaglutide doses reduced serious cardiovascular event risk by 6% compared to tirzepatide.

⚠️ CFRA downgraded Novo Nordisk stock from hold to sell with a $38 price target, citing unfavorable risk-reward and mounting competitive pressure.

🏭 The FDA extended the review of denecimig, a hemophilia A candidate, due to necessary manufacturing site corrections.

πŸ’° Management stated that the delay in denecimig will not affect 2026 financial guidance or the first-half-2027 US launch target.

πŸ“‰ Novo Nordisk shares fell noticeably following skepticism from investors regarding management's long-term growth targets and muted earnings outlook.

Bullish Signals
  • Novo Nordisk released real-world data demonstrating that oral Wegovy provides a meaningful alternative for patients avoiding injections, with users shedding an average of 4.1% body weight over three months.
  • A large retrospective study suggests escalating semaglutide doses lowers the risk of serious cardiovascular events by 6% compared to switching to tirzepatide, strengthening Novo Nordisk's position in the type 2 diabetes market.
Risk Factors
  • CFRA downgraded Novo Nordisk from hold to sell with a $38 price target, citing an unfavorable risk-reward profile and mounting competitive pressure.
  • Investors expressed skepticism regarding management's long-term growth targets, leading to a noticeable decline in shares following the capital markets day.
  • The FDA extended its review of denecimig due to corrective work needed at a manufacturing site, though this delay is not expected to impact 2026 financial guidance.
Full Analysis
Novo Nordisk released fresh real-world data supporting its metabolic franchise, including a retrospective analysis showing that patients switching from injectable to oral Wegovy lost an average of 4.1% body weight over three months via the Ro telehealth platform. The company also published a large-scale study involving over 636,000 adults with type 2 diabetes, finding that escalating semaglutide doses was associated with a 6% lower risk of serious cardiovascular events compared to switching to tirzepatide, bolstering its competitive standing despite the study's inability to prove causation. In its development pipeline, the FDA extended its review of denecimig, a hemophilia A candidate, due to manufacturing site corrections. Management confirmed that this delay will not impact 2026 financial guidance, with the US launch still targeted for the first half of 2027.